Form 4: Myseum Director Shelus Granted Stock Options
Statement of Changes in Beneficial Ownership
Myseum, Inc. Director Peter Shelus was granted 25,000 stock options with a $3 exercise price, vesting semiannually.
Summary
- Director Peter Shelus of Myseum, Inc. (MYSE) was granted 25,000 options to purchase common stock.
- The options have an exercise price of $3 per share.
- The grant was made on August 18, 2025, under the company's Amended and Restated 2021 Equity Incentive Plan.
- The options will vest in four equal semiannual installments, with the first installment vesting six months from the issuance date.
- The options expire on August 18, 2030.
Sentiment
Score: 6
Explanation: Slightly positive. While it introduces potential future dilution, the grant aligns director incentives with shareholder value and is a standard compensation practice, indicating stability in governance.
Positives
- The grant of stock options to Director Peter Shelus aligns his interests with those of the shareholders, incentivizing long-term value creation.
- The options were granted under an existing, approved equity incentive plan, indicating a structured approach to executive compensation.
Negatives
- The exercise of these options in the future could lead to dilution for existing shareholders.
Risks
- Potential future dilution of existing shareholders if the 25,000 options are exercised.
Future Outlook
The options are set to vest in four equal semiannual installments, with the first vesting six months from the grant date, indicating a future schedule for the director's equity accumulation.
Industry Context
Granting stock options to directors is a standard practice across various industries to align management incentives with shareholder interests and is a common component of executive compensation packages.
Comparison to Industry Standards
- The grant of 25,000 options to a director is a common form of non-cash compensation, comparable to practices at similar-sized public companies aiming to retain and incentivize key personnel.
- The vesting schedule of four equal semiannual installments is a typical structure designed to encourage long-term commitment and performance, consistent with industry benchmarks for equity awards.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Grant | Options granted to Director Peter Shelus under the Registrant's Amended and Restated 2021 Equity Incentive Plan. | 08/18/2025 | Aligns director's incentives with shareholder value creation, utilizing an existing approved equity plan, reinforcing corporate governance through performance-based compensation. |
Related Party Transactions
- Grant of stock options to Director Peter Shelus, which constitutes compensation from the company.
Stakeholder Impact
- Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned director incentives.
- Director Peter Shelus: Receives performance-based compensation, incentivizing long-term commitment and performance.
Next Steps
- The options will begin vesting six months from the grant date, with subsequent vesting occurring semiannually.
Key Dates
| Date | Description |
|---|---|
| 08/18/2025 | Date of option grant to Director Peter Shelus. |
| 08/18/2030 | Expiration date of the granted options. |
Keywords
Myseum, MYSE, Stock Options, Equity Incentive Plan, Director Compensation, SEC Form 4, Insider Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.